Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
15.16B | 15.61B | 15.91B | 17.74B | 16.21B | 14.29B | Gross Profit |
11.08B | 11.18B | 11.35B | 13.43B | 12.38B | 10.74B | EBIT |
102.00M | 970.00M | 1.51B | 3.17B | 3.90B | 2.71B | EBITDA |
589.00M | 1.98B | 2.35B | 3.79B | 3.66B | 2.71B | Net Income Common Stockholders |
-700.00M | 390.00M | 1.01B | 2.39B | 2.87B | 684.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
3.40B | 3.40B | 4.03B | 3.96B | 4.96B | 5.02B | Total Assets |
21.68B | 21.68B | 23.41B | 20.91B | 21.97B | 17.78B | Total Debt |
9.83B | 9.83B | 10.17B | 7.64B | 8.10B | 8.79B | Net Debt |
6.43B | 6.43B | 6.14B | 3.69B | 3.14B | 3.77B | Total Liabilities |
16.36B | 16.36B | 17.00B | 14.48B | 15.02B | 13.82B | Stockholders Equity |
5.31B | 5.31B | 5.58B | 5.59B | 6.09B | 3.96B |
Cash Flow | Free Cash Flow | ||||
1.15B | 1.44B | -1.56B | 2.00B | 2.99B | 1.66B | Operating Cash Flow |
1.81B | 2.36B | 1.73B | 3.04B | 3.63B | 2.28B | Investing Cash Flow |
-1.44B | -960.00M | -3.22B | -945.00M | -1.86B | -1.70B | Financing Cash Flow |
-1.69B | -2.04B | 1.52B | -3.04B | -1.89B | 1.46B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $406.08B | 27.59 | 30.25% | 2.29% | 0.49% | 5.02% | |
73 Outperform | $148.52B | 23.28 | 28.73% | 3.21% | 1.99% | -10.59% | |
63 Neutral | $393.80M | ― | -22.50% | 3.13% | -12.04% | -1796.38% | |
62 Neutral | $3.60B | 38.02 | 15.17% | ― | 46.27% | -26.45% | |
60 Neutral | $13.01B | 10.45 | 0.79% | 3.53% | 1.60% | -22.47% | |
57 Neutral | $4.96B | 40.12 | 0.27% | ― | 1.35% | -99.94% | |
50 Neutral | $24.49B | 147.29 | -14.17% | 2.88% | 0.07% | -249.21% |
Ronald S. Lauder has announced his retirement from the Board of Directors of The Estée Lauder Companies effective January 10, 2025, after serving since 2016. The decision was not due to any disagreements, and he will continue as Chairman of Clinique Laboratories LLC. Eric Zinterhofer has been elected as a Class II director to replace him. Mr. Zinterhofer, a founding partner of Searchlight Capital Partners and son-in-law of Mr. Lauder, will be succeeding him under the Stockholders’ Agreement. The agreement, which involves the Lauder family’s significant voting power, ensures continuity in the board’s composition and maintains the family’s influence within the company.